• Home
• News
• About Us
• Contact

Search

Tag Cloud

anthrax Strategic National Stockpile Training exercise Bioterror Biomagnetics National Research Council Homeland Security Biodefense lab Army Medical Research Institute antibiotics Emergency preparedness research Bioweapons NIAID smallpox Detection technology CDC TSA Defense Dept IAEM FEMA immunization Ebola Ricin Hendra Plague treaty West Nile Camouflage Paint Marburg antidote weapons destruction Sarin VHF viruses chemical disposal dna technology prevention Robotics Technology research grants tularemia weapons control foot and mouth disease decontamination E. coli Iraq missile defense Bio-Rescue Dengue fever Botulinum toxin antiviral molecular diagnostics Infectious disease

Subscribe to our newsletter

RSS Feed

Emergency responders should be immunized against anthrax
by Andrew Zaleski on March 8, 2010

Emergency responders arrived at Sen. Tom Daschle’s Capitol Hill office on Oct. 15, 2001 suited in personal protective equipment (PPE).

DoD to fund research into anti-botulism drugs
by Nick Rees on March 5, 2010

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory and Stony Brook University's Institute of Chemical Biology and Drug Discovery have been selected to receive research funds to develop anti-botulism drugs.

Experts respond to Harvard anthrax response study
by Ted Purlain on March 2, 2010

Universal Detection Technology has responded to a recent Harvard School of Public Health poll that found 39 percent of Americans facing a significant anthrax threat would delay taking prophylactic antibiotics.

Anti-vaccine movement could have deadly consequences in the event of an attack
by Tina Redlup on February 16, 2010

The recent anti-vaccine movement, meant to combat the theory that childhood immunizations could be linked to autism, could seriously raise the dangers of the United States' response to potential acts of bioterror, an expert has recently announced.

- DepoVax could mean fewer doses of anthrax vaccine needed
by Nick Rees on February 10, 2010

Immunovaccine Inc. will present positive new research, done in collaboration with Defence Research and Development Canada, that confirms that the number of required doses for an anthrax vaccine candidate can be reduced when formulated in DepoVax.

Effort extended in fight against Lassa virus
by Nick Rees on February 9, 2010

A major extension in the collaborative effort between Corgenix Medical Corporation and Tulane University has been announced to combat viral hemorrhagic fever.

SLU seeks 250 people for smallpox study
by Nick Rees on February 5, 2010

As part of its recently announced project to create a smallpox vaccine to fight bioterrorism, Saint Louis University has begun seeking 250 volunteers to inject with smallpox.

Emergent BioSolutions leading the way in Michigan's drive to propserity
by Paul Tinder on February 4, 2010

The state of Michigan, facing the loss of manufacturing jobs, has turned its eye toward the future and begun exploring innovative methods of restoring prosperity to the region.

Soligenix announces heightened stability for RiVax
by Nick Rees on February 3, 2010

Soligenix, Inc., has announced the publication of an article describing preclinical formulations of RiVax, a ricin toxin vaccine, with heightened stability.

Study begins to find more effective manner of fighting smallpox
by Ted Purlain on February 3, 2010

A more effective manner of administering an investigational vaccine for smallpox will be studied by scientists at Saint Louis University's Center for Vaccine Development in a study funded by the National Institute of Health.

Grant given to fund research into Ebola and Marburg
by Nick Rees on January 7, 2010

Dutch pharmaceutical firm Crucell has awarded a significant contract to Southwest Foundation for Biomedical Research to develop a vaccine for potential bioterror weapons Ebola and Marburg.

Fraunhofer awarded grant to fight anthrax and plague
by Nick Rees on January 7, 2010

Fraunhofer USA Center for Molecular Biotechnology has received a $5.3 million contract to create a vaccine to protect against both anthrax and plague.

U.S. Postal Service to be in charge of drug delivery in the event of a bioattack
by Nick Rees on December 31, 2009

Following an executive order released Wednesday, the U.S. Postal Service will be put in charge of delivering drugs and other medical aid to Americans in the event of a large-scale biological weapon attack.

Third anthrax death in Glasgow
by Pat Dulnier on December 30, 2009

Doctors have confirmed that a heroin user who died last week was infected with anthrax, bringing the total deaths from infections to three.

Fear grows of spread of anthrax in Zimbabwe
by Nick Rees on December 29, 2009

Veterinary officials in Zimbabwe fear that the recent anthrax outbreak is spreading, announcing on Monday that they are testing another suspected case of the disease from a rural growth point approximately 31 miles east of Harare.

La Jolla Institute receives funding to study smallpox threat
by Nick Rees on December 18, 2009

A federally funded, five year, $18.8 million set of projects by researchers at the La Jolla Institute for Allergy & Immunology aims to make inroads on defeating several diseases identified as bioterror threats.

Military researcher infected with tularemia at research laboratory
by Nick Rees on December 9, 2009

A military researcher, working at the United States Army Research Institute of Infectious Diseases, has contracted a laboratory-acquired infection of tularemia.

Anthrax drug Anthim shown to be effective in rabbit and primate studies
by Paul Tinder on December 8, 2009

The biopharmaceutical company Elusys Therapeutics, Inc., has announced positive results for its Anthim anthrax anti-toxin program.

BARDA cancels procurement of rPA vaccines
by Nick Rees on December 8, 2009

The Office of the Biomedical Advanced Research and Development Authority has announced that its Request for Proposal for the procurement of rPA vaccines has been canceled.

Brookline, Mass., stages bioterror drill
by Pat Dulnier on December 3, 2009

More than 100 volunteers will take part in a rapid vaccination program in Brookline, Mass., this weekend to prepare the town for a serious pandemic situation or a bioterrorist attack.

Obama administration announces major review of public health defenses
by Ted Purlain on December 2, 2009

Plans have been announced by a top Obama administration official to proceed with a major review of the federal government's policies for developing public health defenses.

Smallpox vaccine adds to potential biodefense stockpile
by Nick Rees on December 2, 2009

Bavarian Nordic A/S, focusing on biodefense, has announced that it expects to file a new drug submission for Imvamune, its third-generation smallpox vaccine.

Anthrax vaccine project stopped over animal rights
by Nick Rees on November 30, 2009

Oklahoma State University has put a stop to a project meant to test anthrax vaccines and treatment on baboons.

Major smallpox vaccine order announcement expected
by Paul Tinder on November 27, 2009

The biodefense company SIGA Technologies, which engages in the discovery, development and commercialization of products for use in defense against biological warfare agents, is expected to make a major announcement.

Baxter International, Inc., investigates rapid vaccine producing U.S. facility
by Nick Rees on November 27, 2009

Baxter International, Inc., based in Deerfield, Illinois, has begun the investigation process to build a cell-based vaccine manufacturing plant in the U.S.

Immuinzations could act as fire breaks for epidemic
by Nick Rees on November 27, 2009

U.S. Air Force Colonel Randy Larsen has an easy solution to the threat of biological attacks in America - immunize Americans against smallpox and anthrax.

Cowpox's genetic code could lead to bioweapon vaccines
by Tina Redlup on November 25, 2009

Research into deciphering the cowpox virus' genetic coding has revealed the potential to treat other diseases, including those that pose a biothreat such as ebola.

Pundits push for changes in creation of vaccines
by Rita Uplend on November 24, 2009

As the swine flu epidemic continues to steam ahead, leading pundits have begun to apply lessons learned from its spread to potential bioattacks.

Human Genome Sciences, Inc. receives approval for anthrax treatment
by Ted Purlain on November 19, 2009

A Complete Response Letter has been sent to Human Genome Sciences, Inc., from the U.S. Food and Drug Administration about HGS' request for the approval of its treatment for inhalational anthrax.

Anthrax drug's effectiveness questioned
by Nick Rees on November 19, 2009

Federal regulators have questioned the effectiveness of Human Genome Sciences, Inc.'s new anthrax treatment raxibacumab.

Primate research center granted stimulus funds for Marburg and Ebola vaccine study
by Paul Tinder on November 18, 2009

Federal stimulus money has been granted to the New England Primate Research Center for investigations and a contract tied to developing a vaccine for the Marburg and Ebola viruses.

SRI International opens research center in Virginia
by Ted Purlain on November 12, 2009

RI International opened a new facility for its Center for Advanced Drug Research, where scientists will work on developing vaccines, more quickly diagnosing infections and developing new treatments.

Scientists Announce Possible Treatment for Deadly Virus
by Pat Dulnier on November 11, 2009

A team of Australian and U.S. scientists believe they have found an antibody that could protect humans from the deadly Hendra virus, Australia's Northern Miner reported yesterday.

University of Illinois to develop antibiotics against potential bioterrorism agents
by Ted Purlain on November 11, 2009

Researchers at the University of Illinois at Chicago have received a $4 million federal grant to develop new antibiotics to treat anthrax, tularemia and plague, the university announced Nov. 10.

Emergent BioSolutions, FDA review strategy for recombinant anthrax vaccine
by Ted Purlain on June 11, 2009

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced June 11, 2009, that it has met with the U.S. Food and Drug Administration to review its regulatory strategy for the development of its recombinant anthrax vaccine.

FDA approves extending BioThrax’s shelf life to 4 years
by Tina Redlup on June 10, 2009

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced June 10, 2009, that its BioThrax anthrax vaccine has been granted a shelf life extension from three to four years by the U.S. Food and Drug Administration.

Emergent BioSolutions submits its plan for vaccine contract to FDA
by Pat Dulnier on May 13, 2009

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced May 13, 2009, that it has submitted to the U.S. Food and Drug Administration a development plan for the company’s recombinant protective antigen anthrax vaccine candidate.

Emergent BioSolutions launches biothrax.com
by Paul Tinder on May 8, 2009

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced the launch of www.biothrax.com, a website that provides information about BioThrax, the only vaccine licensed by the U.S. FDA for the prevention of anthrax infection.

Emergent BioSolutions acquires advanced anthrax vaccine candidate, technology
by Pat Dulnier on May 5, 2008

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology from VaxGen Inc.

Emergent BioSolutions establishes office in Germany
by Paul Tinder on August 23, 2005

GAITHERSBURG, Md. — Emergent BioSolutions on Aug. 23, 2005, announced the opening of an office in Munich, Germany, dedicated to the expansion of markets throughout Europe and Asia.

Hauer named to Emergent BioSolutions’ board of directors
by Rita Uplend on June 8, 2005

GAITHERSBURG, Md. — Jerome M. Hauer, former acting assistant secretary for the Office of Public and Emergency Preparedness in the U.S. Department of Health and Human Services has been named to its board of directors.